Referral for colposcopic evaluation is an expected consequence that occurs in a small subset of the millions of women who undergo Papanicolaou (Pap) tests annually. At the time of this colposcopic examination, the performance of a repeated Pap test is not uncommon, although the validity and clinical usefulness of this practice remain a matter of debate. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The practice is advocated as a routine measure in some gynecologic texts, advocated under certain circumstances by some, and eschewed entirely in others. [13] [14] [15] [16] [17] [18] The American Society for Colposcopy and Cervical Pathology (ASCCP), in its practice recommendations, urges colposcopy practitioners to "repeat Pap only if this is critical information," 19 and notes that "even a correctly performed Pap smear may irritate the cervix and often causes bleeding." 19 Previous investigations, using a variety of definitions for "clinically useful" repeated cytology, have yielded divergent conclusions regarding its clinical value and/ or cost-effectiveness. [13] [14] [15] [16] [17] [18] The majority of these previous investigations were conducted before the widespread use of liquid-based cytology, which has been associated with improved specimen adequacy rates, with the attendant possibility of an increased rate of detection of high-grade intraepithelial lesions by the repeated cytology. 20 Furthermore, most did not evaluate the potential influence of the intervals between referral and repeated cytology on the overall clinical usefulness of the repeated cytology. In this report of our large-scale retrospective study, we present our experience with a cohort of patients who received a repeated Pap test at the time of first colposcopy and our assessment in a multifaceted manner of the value of repeated cytology in this context.
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Materials and Methods

Case Selection and Inclusion Criteria
This study was approved by the institutional review board at the Brian Allgood Army Community Hospital (BAACH), a US Army medical facility in Yongsan Garrison, Seoul, Republic of Korea. The primary site of data collection was BAACH. An electronic database was queried for archived Pap test and surgical pathology reports from January 2004 to December 2008. Search parameters were designed such that results included only cases in which the Pap test was performed and prepared using liquid-based preparations. ThinPrep Pap tests (Hologic, Bedford, MA) were used almost exclusively during this period. Cytologic interpretations were typically reported using the 2001 Bethesda System. 21 In addition, reports with the terminology "low-grade squamous intraepithelial lesion (LSIL), cannot exclude high-grade squamous intraepithelial lesion (HSIL)" (LSIL-H) were also included. 22, 23 Various pathologists at BAACH or 1 of 2 US Army tertiary care medical centers reviewed all Pap tests requiring a pathologist's interpretation. All histologic specimens were examined at BAACH. Colposcopies were performed by various colposcopy-certified privileged providers, including gynecologists, nurse practitioners, and family physicians. The colposcopic impressions were not recorded, nor were the cytologic or histologic slides reexamined for the purposes of this study.
Study cases included those with a record of an abnormal Pap test (ie, interpretations of atypical squamous cells of undetermined significance [ASC-US] or worse; hereafter referred to as "referral cytology") that was followed by a colposcopic examination in which a Pap test ("repeated cytology") and histologic evaluation (ie, punch biopsy and/ or endocervical curettage) were performed. In addition, only cases in which the colposcopic examination was performed within 12 months of the referral cytology were included. Cases with abnormal referral cytology performed at another institution were included only if the date and specific diagnosis were available. We excluded any cases with a colposcopically directed biopsy and/or excisional procedure performed in the 12-month period that preceded the repeated cytology. For each case, we recorded the following data: patient age, cytologic interpretations, histologic diagnoses, and interval from referral cytology to colposcopy. When available, followup data for cases with HSIL referral and/or repeated cytology were recorded.
Referral/Repeated Cytology Agreement Analysis
An analysis of the level of agreement between referral cytology and repeated cytology was performed. Agreement was considered to be present if the referral cytology and repeated cytology were within the same risk category according to the following definitions: Low-risk cytology included negative for intraepithelial lesion or malignancy (NILM), ASC-US, and LSIL. Intermediate-risk cytology included LSIL-H and atypical squamous cells, cannot exclude HSIL (ASC-H). High-risk cytology included HSIL, atypical glandular cells (AGC), and invasive carcinoma.
Clinical Usefulness of Repeated Cytology
We evaluated the clinical usefulness of repeated cytology at the time of colposcopy by stratifying patients into 4 groups based on their differential risk categorizations for referral cytology vs repeated cytology, respectively: low risk to high risk, low risk to low risk, high risk to high risk, and high risk to low risk. In this analysis, only HSIL was in the highrisk cytology category. Low-risk cytology included NILM, ASC-US, and LSIL. Intermediate-risk cytology (LSIL-H and ASC-H) and AGC, not otherwise specified, were not included to simplify the analysis.
The histologic findings were examined for each group. Repeated cytology was considered "clinically useful" if the results could have conceivably impacted the physician's decision to proceed with or defer a more invasive diagnostic/ therapeutic evaluation, such as the performance of a loop electrosurgical excision procedure (LEEP), based on general practice guidelines. 24, 25 The repeated cytology in the following situations was considered potentially clinically useful: (1) low-grade referral cytology followed by high-grade repeated cytology and a low-grade/negative biopsy result, a scenario that may prompt consideration of a LEEP; (2) high-grade referral cytology with repeated cytology and the biopsy result low-grade or negative, which may prompt deferment of a more invasive diagnostic/therapeutic evaluation; and (3) referral cytology and repeated cytology high-grade with a low-grade or negative biopsy result, potentially prompting greater consideration for a more invasive diagnostic/therapeutic evaluation. Follow-up data, when available, were collected on all the cases in which repeated cytology was deemed potentially clinically useful.
Referral to Repeated Cytology, Time Frame Analysis
We investigated any relationships between the aforementioned 4 groups and the intervals between referral and repeated cytology by classifying the cases into 2 to 4 discrete groups (depending on the analysis): repeated cytology performed in 3 months or less, 4 to 12 months, 3 to 6 months, or 6 to 12 months of the referral cytology and evaluating various parameters of accuracy; overall clinical usefulness for the repeated cytology; and levels of agreement for the referral cytology and repeated cytology within these time frames. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for repeated cytology overall, repeated cytology within 3 months of the referral cytology, and repeated cytology obtained more than 3 months from the referral cytology, all relative to the diagnosis in the concurrently obtained biopsy as the "gold standard."
Separate calculations were made relative to the biopsy diagnosis of cervical intraepithelial neoplasia (CIN) 1 or worse (ie, any intraepithelial neoplasia, category 1), and for CIN 2 or worse (CIN2+, category 2). For category 1 (end point of CIN of any grade), "true-negatives" were defined as a repeated cytology interpretation of NILM and a biopsy diagnosis of "negative for dysplasia"; "true-positives" as a biopsy diagnosis of CIN and a repeated cytology interpretation of ASC-US or worse; "false-positives" as a repeated cytology interpretation of ASC-US or worse and a biopsy diagnosis of negative for dysplasia; and "false-negatives" as a repeated cytology interpretation of NILM with a biopsy diagnosis of CIN of any grade. For category 2 (end point of CIN 2+), true-negatives were defined as a repeated cytology interpretation of NILM, LSIL, or ASC-US and a biopsy diagnosis of negative for dysplasia or CIN 1; true-positives as a repeated cytology interpretation of LSIL-H, ASC-H, or HSIL and a biopsy diagnosis of CIN 2+; false-positives as a repeated cytology interpretation of LSIL-H, ASC-H, or HSIL and a biopsy diagnosis of negative for dysplasia or CIN 1; and false-negatives as a repeated cytology interpretation of NILM, LSIL, ASC-US and a biopsy diagnosis of CIN2+. Sensitivity, specificity, PPV, and NPV were calculated by using conventional definitions and formulas.
Statistical Analysis
Statistical analyses were performed using SPSS for Windows, release 11.5.0 (SPSS, Chicago, IL). The Pearson χ 2 and Fisher exact tests were used for all statistical comparisons as applicable, with a P value of less than .05 deemed significant.
Results
A total of 1,087 cases met the inclusion criteria. The patients' age distribution is outlined in ❚Table 1❚. The correlation between the referral and repeated cytology is shown in ❚Table 2❚. The referral cytology and repeated cytology interpretations with corresponding biopsy results are presented in ❚Table 3❚.
Referral/Repeated Cytology Agreement Analysis
The overall agreement between referral and repeated cytology was 86%, ie, 86% of all cases were in the same risk category in referral and repeated cytology. Agreement values among low-risk, intermediate-risk, and high-risk cases were 92%, 14%, and 41%, respectively. Low-risk referral cytology was followed by intermediate-risk or high-risk repeated cytology in 2% and 5% of the cases, respectively. Conversely, 69% of intermediate-risk and 54% of high-risk referral cases were followed by low-risk repeated cytology. 
Clinical Usefulness of Repeated Cytology
It was estimated that potentially useful clinical information was obtained from the repeated cytology in 3.6% of the 996 cases in this analysis. The changes in risk categories and the findings in the concurrently obtained biopsies are outlined in ❚Table 4❚. Follow-up data for these clinically useful cases are presented in ❚Table 5❚. The results of this analysis are as follows:
Low-risk referral cytology followed by high-risk repeated cytology (LR to HR) was seen in 49 (4.9%) of the 996 cases. The LR group included 16 ASC-US and 33 LSIL referral cytology cases. Of these 49 cases, 10 (20%) had a concurrent negative or low-grade biopsy result. The repeated cytology in these 10 cases (all LSIL referral cytology) therefore provided information that was potentially clinically useful, as defined previously. Follow-up data were available for 7 (70%) of the 10 cases (Table 5 ). Two cases resulted in an immediate excisional procedure (LEEP); 4 were followed by combined cytology and colposcopy; and 1 was followed by colposcopy alone. In 3 of the 7 cases (0.3% of the 996 cases), a histologically confirmed high-grade lesion was identified. Overall, in only 10 (1.8%) of the 546 LSIL referral cases did the repeated cytology provide potentially clinically useful information.
High-risk referral cytology followed by low-risk repeated cytology (HR to LR) comprised 32 (3.2%) of the 996 cases, of which 19 cases (1.9% of the 996 cases) had a concurrent low-grade biopsy result (none were negative). Follow-up data were available for 8 (42%) of the 19 cases. An excisional procedure was performed in 1 of 8 cases. Follow-up failed to reveal any high-grade histologic findings or HSIL cytology in these 8 cases (Table 5 ). The repeated cytology for these 19 cases was classified as potentially clinically useful in that more conservative management may be supported (eg, repeated colposcopy and cytology).
High-risk referral cytology followed by high-risk repeated cytology (HR to HR) comprised 31 (3.1%) of the 996 cases, of which 7 cases (0.7% of the 996 cases) had a concurrent low-grade biopsy result. The repeated cytology for these 7 cases was classified as potentially clinically useful because consideration of a more aggressive therapeutic/diagnostic evaluation such as a LEEP may have been prompted. Followup information was available for 3 of the 7 cases. Of the 3 cases, 1 had referral cytologic diagnosis of HSIL/AGC, favor neoplastic, which was followed by HSIL repeated cytology and low-grade histologic features on the subsequent cone excision. One case was followed by high-grade LEEP findings, and the last case was followed by combined cytology and colposcopy, both with low-grade findings ( ND, nondiagnostic; NILM, negative for intraepithelial lesion or malignancy; UNSAT, unsatisfactory. * Numbers in parenthesis are percentage of all cases in each row. A negative biopsy result is negative for dysplasia; low-grade biopsy result, cervical intraepithelial neoplasia (CIN) 1/human papillomavirus cytopathic effect; and high-grade biopsy result, CIN 2+. † One HSIL/AGC, favor neoplastic, referral cytologic interpretation was followed by HSIL in the repeated cytologic interpretation and CIN 1 in the biopsy interpretation. ‡ One HSIL referral cytologic interpretation was followed by HSIL in the repeated cytologic interpretation and CIN 3 and in situ/invasive endocervical adenocarcinoma in the biopsy interpretation.
findings were low-risk and the concurrent biopsy result was low-grade. Thus, in 30% of the HSIL referral cases, the repeated cytology and biopsy findings could have supported a more conservative management plan (eg, follow-up with colposcopy and cytology as opposed to an immediate excision). Conversely, in 7 (11%) of the 63 HSIL referral cases, the repeated cytology findings were HSIL, while the biopsy revealed a low-grade lesion, another composite of findings that may prompt consideration of a LEEP, if colposcopy was inadequate. Overall, in 26 (41%) of the HSIL referral cases, the repeated cytology provided clinically useful information, while in 37 cases (59%), CIN 2 or 3 was histologically confirmed, and the repeated cytology was noncontributory. We conclude that repeated cytology provided potentially clinically useful information in 36 (3.6%) of the 996 cases, including 10 (20%) of the 49 cases in the LR to HR group, 19 (59%) of the 32 cases in the HR to LR group, and 7 (23%) of the 31 cases in the HR to HR group. If repeated cytology was performed in cases with HSIL referral cytology only, in 41% of the cases (26/63), the repeated cytology may be clinically ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy. * Cases with unsatisfactory repeated cytology (n = 10) or a nondiagnostic biopsy (n = 17) were not included. Low-risk cytology includes ASC-US, LSIL, and NILM; high-risk cytology, HSIL. A negative biopsy result is negative for dysplasia; low-grade biopsy result, cervical intraepithelial neoplasia (CIN) 1/human papillomavirus cytopathic effect; high-grade biopsy result, CIN 2+. † One HSIL referral cytologic interpretation was followed by HSIL in the repeated cytologic interpretation and CIN 3 and in situ/invasive endocervical adenocarcinoma in the biopsy interpretation. One HSIL/AGC, favor neoplastic, referral cytologic interpretation was followed by HSIL in the repeated cytologic interpretation and CIN 1 in the biopsy interpretation.
useful. If repeated cytology was performed in cases with LSIL referral cytology only, in only 1.8% of the cases would the repeated cytology be clinically useful.
Referral to Repeated Cytology, Time Frame Analysis
When the interval to repeated cytology was considered within the framework of a binary classification (≤3 vs 4-12 months), the overall agreement within these 2 groups was similar (85.1% vs 89.6%, respectively) ❚Table 6❚. Among high-risk referral cases, referral/repeated cytology agreement was greater when 4 to 12 months had elapsed before obtaining repeated cytology compared with repeated cytology obtained at 3 months or less (63% [12/19] vs 35% [23/66] ; P = .035, respectively). This was not reflected in the low-and intermediate-risk groups, wherein these time frames were a significant factor in the level of agreement ( Table 6 ). As outlined in ❚Table 7❚, the sensitivity and specificity of repeated cytology in detecting CIN 2+ were 64% and 97%, respectively. These did not differ significantly if the repeated cytology was performed within 3 months of the referral cytology or between 4 and 12 months (Table 7) . A separate analysis was performed in which we evaluated whether the clinical usefulness of the repeated cytology was significantly influenced by the time that had elapsed since the associated referral cytology. Among the cases with a repeated cytology result that we considered clinically useful, the interval to repeated cytology (≤3 vs 4-12 months) was not a significant factor ❚Table 8❚.
A separate analysis was conducted in which we attempted to determine if a switch in risk categories between the referral and repeated cytology is more or less likely to occur if the latter were performed within certain time frames of the referral cytology. The following comparisons were made: 3 months or less vs 4 to 6 months, 4 to 6 months vs more than 6 months, and 3 months or less vs more than 6 months. We found that with the exception of HR to HR in the 4-to 6-month vs more than 6 months comparison, all other comparisons showed higher proportions of cases switching risk categories in the shorter of the comparison time frames. For example, there were 35 (74%) of 47 repeated cytologic examinations performed within 3 months of the referral cytology switching from low risk to high risk in the repeated cytology compared with only 12 (26%) of 47 repeated cytologic examinations performed in the 4-to 6-month time frame making the same switch, a highly significant difference (P < .0001). ❚Table 9❚. We conclude that for high-risk cases, agreement between referral and repeated cytology is more likely to occur if the repeated cytology is performed more than 3 months from the referral cytology. However, in general, a switch in risk categories, the more clinically relevant issue, is most likely to occur in repeated cytology performed within 3 months of the referral cytology.
Discussion
The value of repeating the Pap test at the time of a first colposcopy has been studied on 3 distinct but interrelated fronts: (1) whether the findings from the repeated cytology alter management in a significant subset of women; (2) the overall accuracy of the repeated cytology, especially because unacceptably low accuracy rates render all other considerations moot; and (3) whether any benefits that may be present CIN, cervical intraepithelial neoplasia; NPV, negative predictive value; PPV, positive predictive value, +, or worse. * See the "Materials and Methods" section for definitions of true-positive, false-positive, true-negative, and false-negative. The intervals are the times to colposcopy.
the high-risk referral cytology/high-risk repeated cytology/ low-grade biopsy scenario may contribute to greater consideration of a diagnostic LEEP per ASCCP guidelines, 24 and the repeated cytology in this context therefore provided clinically useful information. The aforementioned studies did not specifically address this scenario. Earlier studies, based primarily on conventional Pap smears, reported that repeated cytology findings may have influenced patient management in 1.2% to 3% of cases. 1, 5, 6 Simsir et al 7 reported that 16% of their eventual HSIL and 28% of their LSIL cases were diagnosed on repeated cytology only (ie, the biopsy was negative). Therefore, regarding the first issue, our findings, in conjunction with those of Alves et al, 11 Rieck et al, 2 and Dolman et al, 12 indicate that repeated cytology may indeed affect the management of a substantial subset of cases (1.8%-3.6% of patients with LSIL referral cytology and 7%-41% of patients with HSIL referral cytology).
The second issue relates to the accuracy of repeated cytology because this issue is germane to all other considerations. The sensitivity and specificity of the repeated cytology in detecting any neoplastic lesion (using the findings in the concurrently obtained biopsy as the gold standard) were found to be 76% and 59% in this study. This is somewhat comparable to the 76.3% (sensitivity) and 93% (specificity) reported by DiBonito et al 26 and the 89.4% (sensitivity) and 64.8% (specificity) reported in a study from the College of American Pathologists. 27 On the question of the ability of repeated cytology to detect the most clinically significant lesion, ie, CIN 2+, our calculated sensitivity, specificity, PPV, and NPV were 64%, 97%, 76%, and 95%, respectively. These findings are comparable to those reported by Alves et al 11 (parallel values, 81.9%, 73.4%, 77.6%, and 78.3%, respectively), Rieck et al 2 (parallel values, 61.8%, 90.0%, 82.8%, and 75.2%, respectively, with final outcome as the gold standard), and Carns and Fadare 28 (parallel values, 50%, 100%, 100%, and 95%, respectively).
The relatively low sensitivity of repeated cytology in detecting CIN 2+ lesions has been noted previously. 3, 9, 29 Wheelock and Kaminski 9 reported that 26% of their negative are of such a magnitude as to alter the overall cost/benefit ratio for the procedure as a routine measure.
In the present study, we classified cases into risk categories and attempted to define scenarios wherein the repeated cytology may have contributed to alterations in management based on current guidelines. 24, 25 We found that repeated cytology provided potentially clinically useful information in 36 (3.6%) of the 996 cases analyzed, including 41% of the HSIL referral cytology cases and 1.8% of the LSIL referral cytology cases. Three contemporary studies, all of which presumably had at least a significant component of liquid-based cytology cases, provide some context for these findings. 2 the CIN 2+ lesion in these cases may or may not be related to the repeated cytology that was done before the biopsy. Regarding the financial implications of repeated cytology, the cost of a single liquid-based Pap test is $45 to $60. 32 Therefore, if the repeated cytology had not been performed on all 1,087 patients, $48,915 to $65,220 could have been saved during this 5-year period. With 2 to 2.75 million colposcopies performed annually each year in the United States, 33 this figure amounts to at least $450 million by conservative estimates ($45 × 2 million colposcopies/year × 5 years). Of course, in our data set, there are downstream additional costs and savings from the 36 cases in which management could have been altered. The total cost of health care for even a single patient with advanced cervical cancer that would otherwise have been found with repeated cytology would obliterate all of the aforementioned savings of $65,220. In our own patient population, the cost of repeated cytology seems justified, but this is largely a matter of opinion. Our data and those from others 2, 11, 12 indicate that repeated cytology provides potentially clinically useful information more frequently in HSIL referral cytology cases. Restricting repeated cytology to referral cytology cases in which a high-grade lesion is a significant consideration (HSIL, invasive carcinoma, ASC-H, LSIL-H, or AGC) is therefore one possible consideration to contain costs, especially because LSIL/ASC-US referrals significantly outnumber the other referrals.
Our study demonstrates that repeated cytology provides potentially clinically useful information in only a small subset of cases (3.6%). However, findings from the repeated cytology could potentially alter management in up to 41% of HSIL referral cases. As such, we advocate repeated cytology as a routine measure, at minimum, in high-risk referral cytology cases. repeated cytology cases turned out to be associated with CIN 2 or 3 in the concurrently obtained biopsy sample, and the sensitivity of repeated cytology in detecting high-grade lesions was 25% in another study. 3 Several investigators have reported that the sensitivity is generally lower in the repeated cytology performed at the time of first colposcopy compared with the referral cytology. 2, 5, 27 One potential explanation is the lack of an aggressive cervical scraping, given the practitioner's knowledge of an impending colposcopic examination and a desire not to damage the cervical surface. 29 Another potential explanation is the interval between referral and repeated cytology. Some authors have found that repeated Pap tests performed within 120 days of the original tend to be less sensitive, 30 whereas others have not found any such correlation. 31 In our study, there was no significant difference in sensitivity, specificity, PPV, or NPV between cases with repeated cytology performed within 3 months of the referral cytology and those in which it was performed between 4 and 12 months of the referral cytology. A switch from low risk in the referral cytology to high risk in the repeated cytology should increase the sensitivity of the latter for high-grade lesions, and this was more likely to be seen in repeated cytologic examinations that were performed within 3 months of the referral cytology (Table 9 ). However, the reverse switch (HR to LR) was also more likely to be seen in repeated cytologic examinations performed within the shorter time frames in our comparisons (Table 9 ). This indicates that on some level, the interval between the referral and the repeated cytology indeed influences the accuracy of the repeated cytology. Studies that do not address the time issue may underestimate the number of repeated cytology cases that contribute clinically useful information. A final potential explanation for the comparatively lower sensitivity (for high-grade lesions) of the repeated cytology is the complete mechanical exfoliation of the high-grade lesion in the referral cytology. This, in addition to possible diagnostic inaccuracy of the referral cytology and/or lesional regression, could explain the lack of finding any HSIL in follow-up of our cases with the high-risk referral cytology/low-risk repeated cytology/low-risk biopsy composite scenario.
The third issue relates to whether any advantage of repeated cytology, which as demonstrated previously is its potential to change management in a subset of cases, justifies the costs of performing this procedure routinely. These costs are at minimum, financial. There is also a possibility of bleeding, 19 which may in turn reduce the sensitivity of the subsequent colposcopic examination. The latter possibility was most likely to be manifested in our cases with high-risk referral cytology/high-risk repeated cytology/low-grade biopsy composite scenario (seen in 7 [0.7%] of 996 cases). Followup information was available for 3 of the 7 cases, of which 2 showed HSIL in a subsequent Pap test. The failure to identify
